📰 Advanced Prostate News
Advanced Prostate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Prostate. Real-time updates on events, politics, business and more.
April 18, 2024
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The
March 12, 2024
PATIENTS IN SCOTLAND WITH AN ADVANCED FORM OF PROSTATE CANCER CAN NOW ACCESS LYNPARZA (OLAPARIB) WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE WITHOUT A BIOMARKER TEST
February 21, 2024
Learn about disparities in the use of second-generation androgen receptor inhibitors for prostate cancer and how to improve outcomes.
January 15, 2024
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.
November 21, 2023
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative...
June 27, 2023
/PRNewswire/ -- The "Cancer Therapies: Global Strategic Business Report" report has been added to ResearchAndMarkets.coms offering. Global Cancer Therapies...
June 1, 2023
LYNPARZA combination reduced the risk of disease progression or death by 76% vs. abiraterone alone First PARP inhibitor approved in combination with a novel hormonal agent underscores clinically... | June 1, 2023
March 13, 2023
Researchers call for better inclusion of people in Africa and with African ancestry in studies on inherited genetics to help address disparities in prostate cancer outcomes.
December 21, 2022
Investegate announcements from AstraZeneca PLC, Lynparza approved in EU for prostate cancer
December 5, 2022
Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who have been treated